Our Team

Meet Our Team:
Industry Leaders in Stroke Treatment

Our leadership team has led and been associated with several successful pharmaceutical and biotechnology companies, bringing over 50 years experience to our laboratories and delivering a novel PEGylation method.
CEO
Dr. Sandeep Athalye
Dr. Athalye, Chief Executive Officer at Prolong Pharmaceuticals, has 25+ years of experience in strategic and operational roles within the global pharmaceutical industry, including clinical development, regulatory strategy, and R&D.
HEAD OF OPERATIONS
Dr. Chandra Rawal
Dr. Rawal, Head of Operations at Prolong and COO at Kashiv Biosciences, has over 17 years of experience in manufacturing and quality management, leading FDA/EU inspections and international teams.
VICE PRESIDENT – R&D
Dr. Ron Jubin
Dr. Jubin, VP of R&D at Prolong Pharmaceuticals, has 20+ years in drug discovery, with pivotal roles at Schering-Plough and PBL Biomedical. He developed interferon proteins and has a PhD in Microbiology.
CHIEF MEDICAL OFFICER
Dr. Kirsten Gruis
Dr. Gruis is Chief Medical Officer at Prolong Pharmaceuticals. She has 15+ years of research experience in academics, pharmaceutical, and biotechnology industries.
DIRECTOR OF CMC - R&D
Dr. Shaunak Pandya
Dr. Pandya, Director of CMC, R&D at Prolong Pharmaceuticals, brings over 10 years of experience in clinical manufacturing and characterization of conjugate biologics and biosimilars.
SENIOR VICE PRESIDENT- REGULATORY
John Pakulski
John Pakulski, SVP of Regulatory Affairs at Prolong Pharmaceuticals and Kashiv Biosciences, has 35+ years in regulatory affairs, leading biosimilars approvals and shaping US biosimilar pathways.

Meet the Medical Advisory Board

Chairman
Dr. Italo Linfante

Director of Interventional Neuroradiology at Baptist Health Miami Neuroscience Institute

Member
Dr. Raul Nogeuira

Director, UPMC Stroke Institute, University Pittsburg Medical Center

Member
Dr. Arvind Sharma

Neurologist, Stroke Specialist

Member
Dr. David Liebeskind

Director of the UCLA Stroke Center

Prolong’s Path to Success

Our Investors

Avtar Investments is a single-family office with extensive experience investing in healthcare  assets including pharmaceuticals, health technology and healthcare services.
visit their website
Tarsadia is an institutional single-family office with a permanent capital base built on deep domain expertise, opportunistic flexibility, and disciplined investment principles.
visit their website

Learn how you can be part of the journey

Join us in revolutionizing treatments for severe
and life-threatening conditions
call us
or
email our team
Address
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA
Phone
(908) 444-4660 direct
(908) 444-4661 fax
Email
info@prolongpharma.com
About Us
Meet ProlongManagement TeamMedical Advisory BoardOur Investors
Sanguinate®
PipelineHow it WorksGlobal Strokes FactsClinical Trials
Resources
PublicationsConferencesNewsReferences
Legal
Copyright Notice
Terms & Conditions
Privacy Policy
Expanded Access Policy
Prolong Pharmaceuticals, LLC does not provide any drug in development to patients unless they have been accepted into one of our ongoing clinical trials.  For more information on our ongoing clinical trials, please contact info@prolongpharma.com